First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results

Jordana K Schmier1, David W Covert21Managing Scientist, Exponent Inc., Alexandria, VA, USA; 2Associate Director, Health Economics, Alcon Research Ltd., Ft. Worth, TX, USAObjective: To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care populati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jordana K Schmier, David W Covert
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e16ff5a2a1004b01bfc547753054c3fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e16ff5a2a1004b01bfc547753054c3fe
record_format	dspace
spelling	oai:doaj.org-article:e16ff5a2a1004b01bfc547753054c3fe2021-12-02T07:20:58ZFirst-year treatment costs among new initiators of topical prostaglandin analogs: pooled results1177-54671177-5483https://doaj.org/article/e16ff5a2a1004b01bfc547753054c3fe2010-05-01T00:00:00Zhttp://www.dovepress.com/first-year-treatment-costs-among-new-initiators-of-topical--a4380https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Jordana K Schmier1, David W Covert21Managing Scientist, Exponent Inc., Alexandria, VA, USA; 2Associate Director, Health Economics, Alcon Research Ltd., Ft. Worth, TX, USAObjective: To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population.Research design and methods: A model was developed to estimate first-year medical costs. Model inputs were based on weighted results from three previous studies. Treatment patterns were derived from a claims database analysis. Published studies were used to estimate visit-related resource use. Costs were obtained from standard sources.Results: Across studies, 27,809 patients met study criteria, 44.2% of whom remained on their index therapy for 12 months. Adjunctive therapy was needed in 22.5%, 18.5%, and 11.9% of bimatoprost, latanoprost, and benzalkonium chloride (BAK)-free travoprost patients, respectively. Median days to initiating adjunctive therapy were 64, 67, and 127 for bimatoprost, latanoprost, and BAK-free travoprost patients. Estimated first-year medical costs were $1,945, $1,803, and $1,730 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis.Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year treatment costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit the ability to project findings to all glaucoma patients.Keywords: costs and cost analysis, drug therapy, combination, glaucoma, prostaglandin analogs Jordana K SchmierDavid W CovertDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 437-445 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Jordana K Schmier David W Covert First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
description	Jordana K Schmier1, David W Covert21Managing Scientist, Exponent Inc., Alexandria, VA, USA; 2Associate Director, Health Economics, Alcon Research Ltd., Ft. Worth, TX, USAObjective: To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population.Research design and methods: A model was developed to estimate first-year medical costs. Model inputs were based on weighted results from three previous studies. Treatment patterns were derived from a claims database analysis. Published studies were used to estimate visit-related resource use. Costs were obtained from standard sources.Results: Across studies, 27,809 patients met study criteria, 44.2% of whom remained on their index therapy for 12 months. Adjunctive therapy was needed in 22.5%, 18.5%, and 11.9% of bimatoprost, latanoprost, and benzalkonium chloride (BAK)-free travoprost patients, respectively. Median days to initiating adjunctive therapy were 64, 67, and 127 for bimatoprost, latanoprost, and BAK-free travoprost patients. Estimated first-year medical costs were $1,945, $1,803, and $1,730 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis.Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year treatment costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit the ability to project findings to all glaucoma patients.Keywords: costs and cost analysis, drug therapy, combination, glaucoma, prostaglandin analogs
format	article
author	Jordana K Schmier David W Covert
author_facet	Jordana K Schmier David W Covert
author_sort	Jordana K Schmier
title	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
title_short	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
title_full	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
title_fullStr	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
title_full_unstemmed	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
title_sort	first-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/e16ff5a2a1004b01bfc547753054c3fe
work_keys_str_mv	AT jordanakschmier firstyeartreatmentcostsamongnewinitiatorsoftopicalprostaglandinanalogspooledresults AT davidwcovert firstyeartreatmentcostsamongnewinitiatorsoftopicalprostaglandinanalogspooledresults
_version_	1718399488537657344

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results

Ejemplares similares